Tick distribution along animal tracks: implication for preventative medicine

Introduction. Tick abundance and the prevalence of the pathogens they carry have been increasing worldwide in the last decades, and is projected to increase even further. Despite the fact that problem is global, there still remain many gaps in the diagnosis and treatment of tick-borne diseases. The best protection from tick-borne pathogens, therefore, is prevention and avoidance of bites. Ticks mobility is limited so that their spatial distribution is strongly correlated with the presence of, especially with large mammals. In this study, the hypothesis was tested that tick abundance is higher on animal tracks in the forests than in adjacent habitats. This is an important issue because there are still several human habits and practices that can decrease the zoonoses risk. For example, during recreation in forest, people should always walk on the paths (including narrow animal’s tracks) instead of wading through bushes. Materials and method. Flagging of animal trails and near control transects were performed simultaneously. Next, collected ticks were counted, sexed and aged. Results. The abundance of ticks was almost 5-fold (Ixodes ricinus) and 3-fold (Dermacentor spp.) higher on animal trails than on adjacent control transects. Conclusions. The results obtained support the hypothesis that ticks are more abundant on pathways than in adjacent habitats. Most likely, the pattern emerges because large mammals, like deer, which are the most important ticks hosts, use forest paths to move across the landscape and frequently move along the same routes. This research sends an important public message that these forest trails are hotspots of disease risk and should be avoided

NMDA antagonists for treating the non-motor symptoms in Parkinson’s disease

Among patients with Parkinsons disease (PD), depression is prevalent and disabling, impacting both health outcomes and quality of life. There is a critical need for alternative pharmacological methods to treat PD depression, as mainstream antidepressant drugs are largely ineffective in this population. Currently, there are no recommendations for the optimal treatment of PD neuropsychiatric symptoms. Given the dual antidepressant and anti-dyskinetic effects of ketamine and other N-methyl-D-aspartate (NMDA) antagonists for PD, this review aims to examine the current evidence of NMDA antagonists for treating neuropsychiatric symptoms, including memantine, amantadine, ketamine, dizoclopine, and d-cycloserine. A comprehensive literature search was conducted using the PubMed database. We also searched the following databases up to March 1, 2018: Ovid MEDLINE, PsycINFO, CINAHL, Google Scholar, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews. The following keywords were used: NMDA antagonist and Parkinsons disease. Two authors independently reviewed the articles identified from the search using specific selection criteria, focusing on studies of mood, psychiatric condition, depression, cognition, and quality of life, and the consensus was reached on the 20 studies included. There is a preliminary evidence that NMDA antagonists may modulate psychiatric symptoms in PD. However, current evidence of psychiatric symptom-modifying effects is inconclusive and requires that further trials be conducted in PD. The repurposing of old NMDA antagonists, such as ketamine for depression and newer therapies, such as rapastinel, suggests that there is an emerging place for modulating the glutamatergic system for treating non-motor symptoms in PD